Gravar-mail: Atomoxetine in the Treatment of Adults with Subthreshold and/or Late Onset Attention‐Deficit Hyperactivity Disorder‐Not Otherwise Specified (ADHD‐NOS): A Prospective Open‐Label 6‐Week Study